200 related articles for article (PubMed ID: 31379588)
1. Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction Network Using a Systems Biology Model.
Li D; Finley SD
Front Physiol; 2019; 10():823. PubMed ID: 31379588
[TBL] [Abstract][Full Text] [Related]
2. Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue.
Rohrs JA; Sulistio CD; Finley SD
NPJ Syst Biol Appl; 2016; 2():16030-. PubMed ID: 28713587
[TBL] [Abstract][Full Text] [Related]
3. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.
Li D; Finley SD
Integr Biol (Camb); 2018 Apr; 10(4):253-269. PubMed ID: 29623971
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors.
Song M; Finley SD
BMC Syst Biol; 2018 Dec; 12(1):145. PubMed ID: 30591051
[TBL] [Abstract][Full Text] [Related]
5. The role of FGF2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production.
Litwin M; Radwańska A; Paprocka M; Kieda C; Dobosz T; Witkiewicz W; Baczyńska D
Mol Cell Biochem; 2015 Dec; 410(1-2):131-42. PubMed ID: 26314253
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
7. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
8. Fine-tuning pro-angiogenic effects of cobalt for simultaneous enhancement of vascular endothelial growth factor secretion and implant neovascularization.
Chai YC; Mendes LF; van Gastel N; Carmeliet G; Luyten FP
Acta Biomater; 2018 May; 72():447-460. PubMed ID: 29626696
[TBL] [Abstract][Full Text] [Related]
9. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization.
Rusnati M; Presta M
Int J Clin Lab Res; 1996; 26(1):15-23. PubMed ID: 8739851
[TBL] [Abstract][Full Text] [Related]
10. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
11. Mathematical Modeling of Cellular Cross-Talk Between Endothelial and Tumor Cells Highlights Counterintuitive Effects of VEGF-Targeted Therapies.
Jain H; Jackson T
Bull Math Biol; 2018 May; 80(5):971-1016. PubMed ID: 28439752
[TBL] [Abstract][Full Text] [Related]
12. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells.
Mousa SA; Lorelli W; Campochiaro PA
J Cell Biochem; 1999 Jul; 74(1):135-43. PubMed ID: 10381270
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release.
van Mil A; Grundmann S; Goumans MJ; Lei Z; Oerlemans MI; Jaksani S; Doevendans PA; Sluijter JP
Cardiovasc Res; 2012 Mar; 93(4):655-65. PubMed ID: 22227154
[TBL] [Abstract][Full Text] [Related]
14. Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling.
Wu Q; Finley SD
J Clin Med; 2020 Apr; 9(5):. PubMed ID: 32357492
[TBL] [Abstract][Full Text] [Related]
15. Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy.
Mac Gabhann F; Ji JW; Popel AS
PLoS Comput Biol; 2006 Sep; 2(9):e127. PubMed ID: 17002494
[TBL] [Abstract][Full Text] [Related]
16. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.
Kay NE; Bone ND; Tschumper RC; Howell KH; Geyer SM; Dewald GW; Hanson CA; Jelinek DF
Leukemia; 2002 May; 16(5):911-9. PubMed ID: 11986954
[TBL] [Abstract][Full Text] [Related]
17. Is copper chelation an effective anti-angiogenic strategy for cancer treatment?
Antoniades V; Sioga A; Dietrich EM; Meditskou S; Ekonomou L; Antoniades K
Med Hypotheses; 2013 Dec; 81(6):1159-63. PubMed ID: 24210000
[TBL] [Abstract][Full Text] [Related]
18. A novel in vitro assay for human angiogenesis.
Brown KJ; Maynes SF; Bezos A; Maguire DJ; Ford MD; Parish CR
Lab Invest; 1996 Oct; 75(4):539-55. PubMed ID: 8874385
[TBL] [Abstract][Full Text] [Related]
19. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.
Haibe Y; Kreidieh M; El Hajj H; Khalifeh I; Mukherji D; Temraz S; Shamseddine A
Front Oncol; 2020; 10():221. PubMed ID: 32175278
[TBL] [Abstract][Full Text] [Related]
20. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
